CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual Meeting
CG Oncology, Inc. - Common stock (CGON)
Company Research
Source: GlobeNewswire
IRVINE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced two late breaking podium presentations on the topline results from BOND-003 Cohort P (BCG-Unresponsive in papillary-only) and first results from CORE-008 Cohort A (BCG-Naïve with carcinoma in situ) as well as three additional posters, will be presented at the Society of Urologic Oncology (SUO) 26th Annual Meeting taking place at the Sheraton Phoenix Downtown, Phoenix, AZ, from December 2 – 5, 2025. "At SUO this year, we will present important new data from across our clinical program in High-Risk BCG-Naïve NMIBC and High-Risk BCG-Unresponsive Ta/T1 disease, including results from BOND-003 Cohort P and CORE-008 Cohort A. These updates further reinforce cretostimogene’s potential as a backbone immunotherapy across
Show less
Read more
Impact Snapshot
Event Time:
CGON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CGON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CGON alerts
High impacting CG Oncology, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
CGON
News
- CG Oncology (NASDAQ:CGON) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..MarketBeat
- CG Oncology: 'Strong Buy' On Earlier Than Expected Completed Recruitment Cretostimogene [Seeking Alpha]Seeking Alpha
- CG Oncology (CGON) Is Up 29.7% After Accelerating PIVOT-006 Phase 3 Timeline - Has The Bull Case Changed? [Yahoo! Finance]Yahoo! Finance
- Is CG Oncology (CGON) Stock Pricing In Its Recent 79% One Year Surge? [Yahoo! Finance]Yahoo! Finance
- CG Oncology (NASDAQ:CGON) was given a new $93.00 price target on by analysts at Morgan Stanley.MarketBeat
CGON
Earnings
- 11/14/25 - In-Line
CGON
Sec Filings
- 1/13/26 - Form 8-K
- 1/13/26 - Form 424B5
- 1/13/26 - Form 4
- CGON's page on the SEC website